Ceapro Inc.

EDMONTON, A0 · CIK 0001680765 · Biotech · Acquired

Bioactive oat-derived ingredients engineered from natural sources

ceapro.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$7.7M
1 Form D · Jul 2016
122 months since last filing
Contracts
—
No federal contracts on record
Patents
1
1 granted · 0 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$7,713,074
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2186BIOSUPERIOR TECHNOLOGY INC——
2187NexImmune, Inc.—$35M
2188Platform Therapeutics, Inc.—$1.8M
2189Ceapro Inc.—$7.7M
2190GREENSTONE BIOSCIENCES, INC.—$10M
2191SILCSBIO LLC——
2192Hemab Therapeutics——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • Gilles GagnonDirector · Executive Officer
  • Ulrich KosciessaDirector
  • William LiDirector
  • Donald OborowskyDirector
  • Stacy PrefontaineExecutive Officer
  • Glenn RourkeDirector
  • John ZupancicDirector

Patents

USPTO · 1 granted of 1

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.